Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears

• Abivax stock is taking a hit today. Why is ABVX stock falling?The French biotech firm has been at the center of takeover rumors for months, with analysts identifying it as a potential acquisition target for large pharmaceutical companies.Eli Lilly and Co (NYSE:LLY) previously expressed interest.But management's latest comments suggest the company is not under pressure to sell and is instead focused on strengthening its financial position ahead of a potential commercialization phase.Upcoming Trial Seen As ...